1. Home
  2. MREO vs SACH Comparison

MREO vs SACH Comparison

Compare MREO & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc

SELL

Current Price

$0.30

Market Cap

50.3M

Sector

Health Care

ML Signal

SELL

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

HOLD

Current Price

$0.64

Market Cap

40.6M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
MREO
SACH
Founded
2015
2010
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
50.3M
40.6M
IPO Year
2017
2016

Fundamental Metrics

Financial Performance
Metric
MREO
SACH
Price
$0.30
$0.64
Analyst Decision
Buy
Analyst Count
8
0
Target Price
★ $1.96
N/A
AVG Volume (30 Days)
★ 632.5K
125.4K
Earning Date
11-09-2026
11-27-2026
Dividend Yield
N/A
★ 5.76%
EPS Growth
16.67
★ 104.30
EPS
★ N/A
N/A
Revenue
$500,000.00
★ $57,500,000.00
Revenue This Year
$59.51
$94.91
Revenue Next Year
$2,326.81
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.20
$0.69
52 Week High
$2.37
$1.45

Technical Indicators

Market Signals
Indicator
MREO
SACH
Relative Strength Index (RSI) 50.90 13.24
Support Level $0.27 N/A
Resistance Level $0.35 $0.87
Average True Range (ATR) 0.02 0.03
MACD 0.00 -0.02
Stochastic Oscillator 62.55 8.71

Price Performance

Historical Comparison
MREO
SACH

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.

Share on Social Networks: